Esmya ulipristal acetate regulatory update

The European Commission approved an MAA for Esmya ulipristal acetate from PregLem S.A. to treat moderate to severe uterine fibroids in women of reproductive age. PregLem is part of Gedeon Richter. Richter gained the selective progesterone receptor modulator (SPRM) through its 2010 acquisition of PregLem, which had European rights to Esmya to treat gynecological indications, excluding contraception, from HRA Pharma as well as North American rights to the compound for benign gynecological disorders. ...